- Home
- NDMO vs PHAR Comparison
NDMO vs PHAR Comparison
Compare NDMO & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- PHAR
- Stock Information
- Founded
- NDMO 2019
- PHAR 1988
- Country
- NDMO United States
- PHAR Netherlands
- Employees
- NDMO N/A
- PHAR N/A
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NDMO Finance
- PHAR Health Care
- Exchange
- NDMO Nasdaq
- PHAR Nasdaq
- Market Cap
- NDMO N/A
- PHAR 718.1M
- IPO Year
- NDMO N/A
- PHAR N/A
- Fundamental
- Price
- NDMO $10.20
- PHAR $10.27
- Analyst Decision
- NDMO
- PHAR Strong Buy
- Analyst Count
- NDMO 0
- PHAR 3
- Target Price
- NDMO N/A
- PHAR $30.00
- AVG Volume (30 Days)
- NDMO 218.6K
- PHAR 4.3K
- Earning Date
- NDMO 01-01-0001
- PHAR 07-31-2025
- Dividend Yield
- NDMO 6.75%
- PHAR N/A
- EPS Growth
- NDMO N/A
- PHAR N/A
- EPS
- NDMO N/A
- PHAR N/A
- Revenue
- NDMO N/A
- PHAR $320,708,000.00
- Revenue This Year
- NDMO N/A
- PHAR $13.31
- Revenue Next Year
- NDMO N/A
- PHAR $7.68
- P/E Ratio
- NDMO N/A
- PHAR N/A
- Revenue Growth
- NDMO N/A
- PHAR 24.13
- 52 Week Low
- NDMO $8.99
- PHAR $6.65
- 52 Week High
- NDMO $11.24
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- NDMO 60.07
- PHAR 48.21
- Support Level
- NDMO $9.95
- PHAR $10.46
- Resistance Level
- NDMO $10.04
- PHAR $11.49
- Average True Range (ATR)
- NDMO 0.10
- PHAR 0.37
- MACD
- NDMO 0.01
- PHAR -0.12
- Stochastic Oscillator
- NDMO 75.76
- PHAR 27.62
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.